CosLab – About us

For many years, the CosLab Laboratory has specialized in the commercial creation and implementation of formulas and technologies for the production of chemicals and the processing of substances of natural origin. CosLab’s pharmaceutical achievements also include the development of a drug for psoriasis and vitiligo, an antidepressant against compulsive overeating and a fast-acting anaesthesia gel for use in surgical procedures.

Our laboratory has also developed many formulas for medical purposes, dietary supplements, cosmetics, as well as disinfection and biocidal products. Many of these have been patented by their buyers.

In February 2020, CosLab created a separate research and implementation unit to develop measures to fight the 2019 coronavirus epidemic (nCov and its derivatives). The aim of the unit was not to develop a drug, but a series of preventive and protective measures; with particular emphasis on the Septex Protective Mist aerosol spray. In the formula developed in March, as well as pure ethanol, chloride and polymer, for the first time rosemary extract (for a pleasant aroma) and low-concentration synthetic rosemary acid were used. The results of the research were so positively surprising that the laboratory began researching the action of rosmarinic acid as a potential cure for the coronavirus.

Several months of work resulted in the filing of a patent and the commencement of research cooperation with CMUJ, through the person of a clinical pharmacologist, Dr. Jarosław Woroń.

The USP and essential value of the CosLab laboratory lay in its considerable knowledge of substances of plant origin. Plant-based intellectual property and solutions are seldom given much consideration, due to a generally unfavorable attitude in the marketplace. This includes prejudices regarding such things as standardization.

However, from the very beginning of the RoNaVir implementation concept, biotechnologically obtained rosmarinic acid – therefore, fully standardized – was used. Our team has started preliminary research. The results have been so surprisingly successful that we have decided to continue in this direction. Also, we decided to share our discovery with all interested parties, believing that our work and knowledge will contribute to reducing human suffering and help end this current period of helplessness and despair.

Prof.dr hab.inż.Elżbieta Pisulewska

Prof.dr hab.inż.Elżbieta Pisulewska

Uniwersytet Rolniczy

Dr hab. Jarosław Woroń

Dr hab. Jarosław Woroń

Zakład Farmakologii CM UJ

Dr med. Barbara Wnuk

Dr med. Barbara Wnuk

Synthanalytica

mgr Anna Molenda Skowronek

mgr Anna Molenda Skowronek

Laboratorium CosLab

mgr inż. Ewelina Szczepanik

mgr inż. Ewelina Szczepanik

Skin Lab Intl

mgr inż. Michał Skowronek

mgr inż. Michał Skowronek

Laboratorium CosLab

RoNaVir

COMPOSITION CONTAINING ROSEMARINIC ACID AND THE USE OF ROSEMARINIC ACID IN CORONAVIRUS TREATMENT

RoNaVir® is a prototype of an antiviral drug that increases the body’s resistance to infection caused by SARS-CoV-2 virus. Its formula is based on rosmarinic acid, which has a therapeutic effect in the case of drug resistance and mutation of the virus. In addition, it also has a wide adaptability and is considered a safe substance and non-toxic in the maximum daily doses used in therapy.

Due to the fact that the action of RoNaVir® is based on enhancing and increasing the activity of ACE-2 protein receptors embedded in the human cell membrane, it effectively inhibits the synthesis of viral proteins and RNA replication, as well as the adsorption of viruses on the surface of host cells. The ACE-2 protein protects the blood vessels, heart, brain, lungs, kidneys and bone marrow from many types of damage, inhibits inflammation, prevents thrombosis and enables scar-free healing. Since ACE-2 is a major component of virus entry into cells, it is extremely important to stimulate the activity of this protein to prevent or reduce the severity of COVID-19 disease caused by the SARS-CoV-2 coronavirus.

RoNaVir® contains the active ingredient rosmarinic acid, which fights and alleviates the symptoms of COVID-19 or prevents SARS-CoV-2 infection. RoNaVir® is a gelatin capsule, taken orally, containing 100 mg of rosmarinic acid (as the main ingredient) with a purity of 96%. The greatest efficiency is obtained when the purity of this substance is 96% or greater. Rosmarinic acid placed in the capsule at room temperature is a solid as an off-white, pale yellow to beige or light brown powder.

The daily dose of the pharmaceutical is in the range of 100 mg to 1500 mg (the usual dose is 200 mg or 300 mg per day). Duration of treatment may vary between patients, but is usually 4-5 days. Treatment should continue for as long as your doctor tells you to.

The indication for the use of RoNaVir® is the occurrence of typical symptoms caused by SARS-CoV-2 infection. The most common symptoms are fever, dry cough, shallow breathing and tiredness. Symptoms such as headache, sputum production, hemoptysis, chills, diarrhea, chest pain, sore throat, diarrhea, nausea and vomiting are less common. Most cases of the disease are mild, but in some infected it can lead to pneumonia or multi-organ failure.

The effect of the prototype of the drug with 96% rosmarinic acid is currently confirmed by in vivo pre-clinical tests among a group of researchers, people showing typical symptoms of coronavirus infection. On their basis, the 99% effectiveness of RoNaVir® in reducing symptoms in the course of SARS-CoV-2 infection was demonstrated. The health condition of the studied group of people improved significantly by normalizing the body temperature to 36.6 oC, relieving headache, fatigue, shortness of breath and cough, as well as the feeling of depression, fear and confusion.

Currently, there is no specific treatment for disease caused by SARS-CoV-2 infection. Treatment is symptomatic, supportive, and experimental. Symptomatic treatment aims to control symptoms and support body function. Although vaccines to prevent COVID-19 infection have been developed in Europe, Asia (e.g. Russia, China) and North America (USA), they must be approved by the European Medicines Agency. The commencement of vaccinations against Covid-19 does not in any way change the necessity to continue searching for an effective drug.

A variety of substances are known in the art for alleviating the symptoms of SARS-CoV-2 infection, but rosmarinic acid has not yet been used for this purpose. The present inventors have found that an effective dose of rosmarinic acid treats, alleviates the symptoms associated with SARS-CoV-2 virus infection and also prevents this infection. From a pharmacological point of view, the potential uses of rosmarinic acid are much greater due to the fact that it is well absorbed when administered by injection, by the oral route and through the skin. It penetrates deeper skin layers and blood vessels, from where it is transferred to various tissues (including muscle and bone).

Rosmarinic Acid is a substance of natural origin, also currently obtained through biotechnological synthesis, which gives the possibility of obtaining almost 98% high concentration. It is a potentially easy-to-obtain substance and thus may be widely available. It does not require special storage and transport conditions.

CAUTION

RoNaVir® is only a prototype drug in the initial phase of research, it is not available for sale or distribution. The data was shared by CosLab for scientific exchange. However, due to the fact that rosmarinic acid is a commercially available chemical, the publication of such research data does not constitute any risk or form of advertising.

CosLab Sp.z o.o
Ul. Zacisze 6 , 31-156 Kraków
Centrum Badawczo Rozwojowe Oddział w Czernichowie
Ul. Parkowa 27, 32-070 Czernichów
KRS 0000501252 NIP 6762474797
kontakt@coslab.pl Tel. +48 79 77 00 990
biuro@coslab.pl Tel. +48 504 219 865

UA-166950492-1